Core Insights - Pfizer has strengthened its R&D pipeline through mergers and acquisitions (M&A) and successful clinical trials over the past decade [1] - The company expects to have eight or more blockbuster oncology medicines in its portfolio by 2030 [4][10] Oncology Pipeline - Pfizer has advanced its oncology pipeline with several candidates in late-stage development, including vepdegestrant, atirmociclib, and sigvotatug vedotin [2][10] - Sasanlimab is under review for high-risk non-muscle invasive bladder cancer, and Pfizer has exclusive rights to develop SSGJ-707, a dual PD-1 and VEGF inhibitor [3] Recent Approvals and Growth - In 2023, Pfizer achieved a record with nine new medicine/vaccine approvals, and in 2024, it gained approval for a gene therapy for hemophilia [5][10] - New products are contributing to top-line growth, and the company maintains a robust R&D pipeline with potential blockbuster drugs [6] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers, each with significant oncology sales contributing to their overall revenues [8][9][11] Financial Performance - Pfizer's stock has declined 1.2% in 2023, while the industry has seen a 1.5% increase [12] - The company's shares are trading at a price/earnings ratio of 8.01, lower than the industry average of 14.75 and its own 5-year mean of 10.71 [13] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings has increased from $3.05 to $3.13 per share, while the estimate for 2026 remains stable at $3.09 [14]